$5M Bet On Pyxis Oncology? Check Out These 4 Penny Stocks Insiders Are Buying

The Dow Jones closed higher by more than 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

Champions Oncology

• The Trade: Champions Oncology, Inc. CSBR CEO Ronnie Morris acquired a total of 12,382 shares an average price of $4.04. To acquire these shares, it cost around $49.97 thousand.
• What’s Happening: Champions Oncology posted a wider-than-expected quarterly loss.
• What Champions Oncology Does: Champions Oncology Inc is a us-based company which is engaged in the development and sale of advanced technology solutions and products to personalize the development and use of oncology drugs.

Bird Global

• The Trade: Bird Global, Inc. BRDS Director Travis Vanderzanden acquired a total of 1,000,000 shares at an average price of $0.13. The insider spent around $130 thousand to buy those shares.
• What’s Happening: Bird Global reported better-than-expected Q4 sales results.
• What Bird Global Does: Bird Global Inc is a micro-mobility company engaged in delivering electric transportation solutions for short distances.

Check This Out: Top 3 Consumer Stocks That You May Want To Dump In March

Pyxis Oncology

• The Trade: Pyxis Oncology, Inc. PYXS 10% owner Pfizer Ventures (US) LLC acquired a total of 1,811,594 shares at an average price of $2.76. To acquire these shares, it cost around $5 million.
• What’s Happening: Pyxis Oncology said it dosed first subject in Phase 1 trial of PYX-201, a novel ADC for solid tumors.
• What Pyxis Oncology Does: Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients.

Don’t forget to check out our premarket coverage here

The Oncology Institute

• The Trade: The Oncology Institute, Inc. TOI Director Richard Barasch acquired a total of 50,000 shares at an average price of $0.55. The insider spent $27.5 thousand to buy those shares.
• What’s Happening: The Oncology Institute reported better-than-expected Q4 results.
• What The Oncology Institute Does: The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education.